Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

Executive Summary

• Bright Minds Biosciences announced a $100 million public offering of common shares and optional pre‑funded warrants.
• The company granted underwriters a 30‑day option to purchase up to an additional 15% of the offered shares.
• Net proceeds are earmarked for upcoming clinical trials (absence seizures, DEE, Prader‑Willi Syndrome, Phase 1 BMB‑105) and broader R&D and working capital needs.

Key Details

• Offering Size: Aggregate gross proceeds of US$100 million.
• Securities Offered: Common shares; investors may elect pre‑funded warrants to purchase the same shares.
• Underwriter Option: 30‑day option for underwriters to buy up to 15% additional common shares.
• Book‑Running Managers: Jefferies, TD Cowen, Piper Sandler & Co., and Cantor.
• Registration: Shelf registration statement on Form F‑3 declared effective September 2 2025; offering made via prospectus and supplement.
• Use of Proceeds:
• Fund future clinical trials for drug candidates targeting absence seizures, DEE, Prader‑Willi Syndrome.
• Initiate Phase 1 trial for BMB‑105.
• Support additional early‑phase R&D programs.
• General corporate and working capital purposes.
• Contact Persons:
• Alex Vasilkevich – Chief Operating Officer (414‑731‑6422, [email protected])
• Lisa M. Wilson – Investor Relations (212‑452‑2793, [email protected])

Notable Quotes

• (No direct quotes were included in the release.)